- Home
- FLGT vs PRLD Comparison
FLGT vs PRLD Comparison
Compare FLGT & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLGT | PRLD |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 511.0M | 529.1M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FLGT | PRLD |
|---|---|---|
| Price | $19.59 | $5.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $28.33 | $5.67 |
| AVG Volume (30 Days) | 234.6K | ★ 508.3K |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,730,000.00 | $12,140,000.00 |
| Revenue This Year | $10.09 | $320.10 |
| Revenue Next Year | $12.18 | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $13.46 | $0.98 |
| 52 Week High | $31.04 | $6.83 |
Technical Indicators
Market Signals| Indicator | FLGT | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 54.14 | 49.78 |
| Support Level | $19.20 | $3.75 |
| Resistance Level | $20.24 | $5.69 |
| Average True Range (ATR) | 0.54 | 0.50 |
| MACD | 0.07 | -0.09 |
| Stochastic Oscillator | 66.52 | 20.83 |
Price Performance
Historical ComparisonAbout FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.